Direct action of endothelin-1 on podocytes promotes diabetic glomerulosclerosis

Journal of the American Society of Nephrology

Volumn 25, Issue 5, 2014, Pages 1050-1062

  Lenoir, Olivia ^a,b   Milon, Marine ^a,b   Virsolvy, Anne ^a   Hénique, Carole ^a,b   Schmitt, Alain ^b,c,d   Massé, Jean Marc ^b,c,d   Kotelevtsev, Yuri ^e,f   Yanagisawa, Masashi ^g   Webb, David J ^e   Richard, Sylvain ^a   Tharaux, Pierre Louis ^a,b,h  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSTITUT COCHIN   (France)

^d CNRS   (France)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

^f PUSHCHINO STATE UNIVERSITY   (Russian Federation)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CALCIUM; CREATININE; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ALBUMINURIA; ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CELL LOSS; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; GENE DELETION; GLOMERULOSCLEROSIS; GLOMERULUS BASEMENT MEMBRANE; IN VITRO STUDY; KIDNEY FUNCTION; MALE; MICROALBUMINURIA; MOUSE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; UREA NITROGEN BLOOD LEVEL; WILD TYPE MOUSE; ANIMAL; C57BL MOUSE; DOWN REGULATION; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; BETA CATENIN; DIABETIC NEPHROPATHIES; DOWN-REGULATION; ENDOTHELIN-1; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NF-KAPPA B; PODOCYTES; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; SIGNAL TRANSDUCTION;

EID: 84906542664     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2013020195     Document Type: Article

References (67)

1. Van Buren PN, Toto R: Current update in the management of diabetic nephropathy. Curr Diabetes Rev 9: 62-77, 2013
2. Ziyadeh FN, Hoffman BB, Han DC, Iglesias-De La Cruz MC, Hong SW, Isono M, Chen S, McGowan TA, Sharma K: Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci U S A 97: 8015-8020, 2000
3. Ziyadeh FN: Mediators of diabetic renal disease: The case for tgf-Beta as the major mediator. J Am Soc Nephrol 15[Suppl 1]: S55-S57, 2004
4. Najafian B, Alpers CE, Fogo AB: Pathology of human diabetic nephropathy. Contrib Nephrol 170: 36-47, 2011
5. Detournay B, Simon D, Guillausseau PJ, Joly D, Verges B, Attali C, Clement O, Briand Y, Delaitre O: Chronic kidney disease in type 2 diabetes patients in France: Prevalence, influence of glycaemic control and implications for the pharmacological management of diabetes. Diabetes Metab 38: 102-112, 2012
6. Shepler B, Nash C, Smith C, Dimarco A, Petty J, Szewciw S: Update on potential drugs for the treatment of diabetic kidney disease. Clin Ther 34: 1237-1246, 2012
7. Ritz E: Limitations and future treatment options in type 2 diabetes with renal impairment. Diabetes Care 34[Suppl 2]: S330-S334, 2011
8. Fligny C, Barton M, Tharaux PL: Endothelin and podocyte injury in chronic kidney disease. Contrib Nephrol 172: 120-138, 2011
9. Dhaun N, Goddard J, Kohan DE, Pollock DM, Schiffrin EL, Webb DJ: Role of endothelin-1 in clinical hypertension: 20 years on. Hypertension 52: 452-459, 2008
10. GerstungM, Roth T,DienesHP, Licht C, Fries JW: Endothelin-1 induces NF-kappaB via two independent pathways in human renal tubular epithelial cells. Am J Nephrol 27: 294-300, 2007
11. Sugden PH, Clerk A: Endothelin signalling in the cardiac myocyte and its pathophysiological relevance. Curr Vasc Pharmacol 3: 343-351, 2005
12. Bouallegue A, Daou GB, Srivastava AK: Endothelin-1-induced signaling pathways in vascular smooth muscle cells. Curr Vasc Pharmacol 5: 45-52, 2007
13. Sorokin A: Endothelin signaling and actions in the renal mesangium. Contrib Nephrol 172: 50-62, 2011
14. Lehrke I, Waldherr R, Ritz E, Wagner J: Renal endothelin-1 and endothelin receptor type B expression in glomerular diseases with proteinuria. J Am Soc Nephrol 12: 2321-2329, 2001
15. Karet FE, Kuc RE, Davenport AP: Novel ligands BQ123 and BQ3020 characterize endothelin receptor subtypes ETA and ETB in human kidney. Kidney Int 44: 36-42, 1993
16. Yamamoto T, Hirohama T, Uemura H: Endothelin B receptor-like immunoreactivity in podocytes of the rat kidney. Arch Histol Cytol 65: 245-250, 2002
17. Wendel M, Knels L, Kummer W, Koch T: Distribution of endothelin receptor subtypes ETA and ETB in the rat kidney. J Histochem Cytochem 54: 1193-1203, 2006
18. SimonsonMS: Endothelins: Multifunctional renal peptides. Physiol Rev 73: 375-411, 1993
19. Badr KF, Murray JJ, Breyer MD, Takahashi K, Inagami T, Harris RC: Mesangial cell, glomerular and renal vascular responses to endothelin in the rat kidney. Elucidation of signal transduction pathways. J Clin Invest 83: 336-342, 1989
20. Fukuda K, Yanagida T,Okuda S, Tamaki K, Ando T, FujishimaM: Role of endothelin as a mitogen in experimental glomerulonephritis in rats. Kidney Int 49: 1320-1329, 1996
21. Fukui M, Nakamura T, Ebihara I, Osada S, Tomino Y, Masaki T, Goto K, Furuichi Y, Koide H: Gene expression for endothelins and their receptors in glomeruli of diabetic rats. J Lab Clin Med 122: 149-156, 1993
22. Hargrove GM, Dufresne J, Whiteside C, Muruve DA, Wong NC: Diabetesmellitus increases endothelin-1 gene transcription in rat kidney. Kidney Int 58: 1534-1545, 2000
23. Itoh Y,Nakai A, Kakizawa H,MakinoM, Fujiwara K, Kobayashi T, Kato T, Nagata M, Oda N, Katsumata H, Nagasaka A, Itoh M: Alteration of endothelin-1 concentration in STZ-induced diabetic rat nephropathy. Effects of a PGI(2) derivative. Horm Res 56: 165-171, 2001
24. Bruno CM, Meli S, Marcinno M, Ierna D, Sciacca C, Neri S: Plasma endothelin-1 levels and albumin excretion rate in normotensive, microalbuminuric type 2 diabetic patients. J Biol Regul Homeost Agents 16: 114-117, 2002
25. Zanatta CM, Veronese FV, LoretoMS, SorticaDA, Carpio VN, Eldeweiss MI, da Silva VD, Lopes TG, Gross JL, Canani LH: Endothelin-1 and endothelin A receptor immunoreactivity is increased in patients with diabetic nephropathy. Ren Fail 34: 308-315, 2012
26. Mishra R, Emancipator SN, Kern TS, Simonson MS: Association between endothelin-1 and collagen deposition in db/db diabetic mouse kidneys. Biochem Biophys Res Commun 339: 65-70, 2006
27. Ding SS, Qiu C, Hess P, Xi JF, Zheng N, Clozel M: Chronic endothelin receptor blockade prevents both early hyperfiltration and late overt diabetic nephropathy in the rat. J Cardiovasc Pharmacol 42: 48-54, 2003
28. Cosenzi A, Bernobich E, Trevisan R, Milutinovic N, Borri A, Bellini G: Nephroprotective effect of bosentan in diabetic rats. J Cardiovasc Pharmacol 42: 752-756, 2003
29. Sasser JM, Sullivan JC, Hobbs JL, Yamamoto T, Pollock DM, Carmines PK, Pollock JS: Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism. J Am Soc Nephrol 18: 143-154, 2007
30. Saleh MA, Boesen EI, Pollock JS, Savin VJ, PollockDM: Endothelin receptor A-specific stimulation of glomerular inflammation and injury in a streptozotocin-induced rat model of diabetes. Diabetologia 54: 979-988, 2011
31. Sarafidis PA, Lasaridis AN: Diabetic nephropathy: Endothelin antagonism for diabetic nephropathy. Nat Rev Nephrol 6: 447-449, 2010
32. Benz K, Amann K: Endothelin in diabetic renal disease. Contrib Nephrol 172: 139-148, 2011
33. Kohan DE, Pollock DM: Endothelin antagonists for diabetic and nondiabetic chronic kidney disease. Br J Clin Pharmacol 76: 573-579, 2013
34. Ritz E, Wenzel RR: Endothelin antagonist as add-on treatment for proteinuria in diabetic nephropathy: Is there light at the end of the tunnel? J Am Soc Nephrol 22: 593-595, 2011
35. Kohan DE, Pritchett Y, Molitch M, Wen S, Garimella T, Audhya P, Andress DL: Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol 22: 763-772, 2011
36. Gagliardini E, Corna D, Zoja C, Sangalli F, Carrara F, Rossi M, Conti S, Rottoli D, Longaretti L, Remuzzi A, Remuzzi G, Benigni A: Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes. Am J Physiol Renal Physiol 297: F1448-F1456, 2009
37. Moeller MJ, Sanden SK, Soofi A, Wiggins RC, Holzman LB: Podocytespecific expression of Cre recombinase in transgenicmice. Genesis 35: 39-42, 2003
38. Kapoor M, Liu S, Shi-wen X, Huh K, McCann M, Denton CP, Woodgett JR, Abraham DJ, Leask A: GSK-3beta in mouse fibroblasts controls wound healing and fibrosis through an endothelin-1-dependent mechanism. J Clin Invest 118: 3279-3290, 2008
39. Rosanò L, Cianfrocca R, Masi S, Spinella F, Di Castro V, Biroccio A, Salvati E,NicotraMR,Natali PG, Bagnato A: Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis. Proc Natl Acad Sci U S A 106: 2806-2811, 2009
40. Rosanò L, Cianfrocca R, Tocci P, Spinella F, Di Castro V, Spadaro F, Salvati E, Biroccio AM, Natali PG, Bagnato A: b-arrestin-1 is a nuclear transcriptional regulator of endothelin-1-induced b-catenin signaling. Oncogene 32: 5066-5077, 2013
41. Kao YS, Fong JC: A novel cross-talk between endothelin-1 and cyclic AMP signaling pathways in the regulation of GLUT1 transcription in 3T3-L1 adipocytes. Cell Signal 23: 901-910, 2011
42. Dai C, Stolz DB, Kiss LP, Monga SP, Holzman LB, Liu Y: Wnt/betacatenin signaling promotes podocyte dysfunction and albuminuria. J Am Soc Nephrol 20: 1997-2008, 2009
43. Kato H, Gruenwald A, Suh JH, Miner JH, Barisoni-Thomas L, Taketo MM, Faul C, Millar SE, Holzman LB, Susztak K: Wnt/b-catenin pathway in podocytes integrates cell adhesion, differentiation, and survival. J Biol Chem 286: 26003-26015, 2011
44. Tsiani E, Lekas P, Fantus IG, Dlugosz J, Whiteside C: High glucoseenhanced activation of mesangial cell p38 MAPK by ET-1, ANG II, and platelet-derived growth factor. Am J Physiol Endocrinol Metab 282: E161-E169, 2002
45. Morigi M, Buelli S, Angioletti S, Zanchi C, Longaretti L, Zoja C, GalbuseraM, Gastoldi S, Mundel P, RemuzziG, Benigni A: In response to protein load podocytes reorganize cytoskeleton and modulate endothelin-1 gene: Implication for permselective dysfunction of chronic nephropathies. Am J Pathol 166: 1309-1320, 2005
46. MorigiM, Buelli S, Zanchi C, Longaretti L,Macconi D, Benigni A,Moioli D, Remuzzi G, Zoja C: Shigatoxin-induced endothelin-1 expression in cultured podocytes autocrinally mediates actin remodeling. Am J Pathol 169: 1965-1975, 2006
47. Ortmann J, Amann K, Brandes RP, Kretzler M, Münter K, Parekh N, Traupe T, Lange M, Lattmann T, Barton M: Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition. Hypertension 44: 974-981, 2004
48. Evans NJ, Walker JW: Sustained Ca2+ signaling and delayed internalization associated with endothelin receptor heterodimers linked through a PDZ finger. Can J Physiol Pharmacol 86: 526-535, 2008
49. Evans NJ, Walker JW: Endothelin receptor dimers evaluated by FRET, ligand binding, and calciummobilization. Biophys J 95: 483-492, 2008
50. Sauvageau S, Thorin E, Caron A, Dupuis J: Evaluation of endothelin-1-induced pulmonary vasoconstriction following myocardial infarction. Exp Biol Med (Maywood) 231: 840-846, 2006
51. Dhaun N, Macintyre IM, Melville V, Lilitkarntakul P, Johnston NR, Goddard J, Webb DJ: Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-a receptor antagonism in chronic kidney disease. Hypertension 54: 113-119, 2009
52. Neuhofer W, Pittrow D: Endothelin receptor selectivity in chronic kidney disease: Rationale and review of recent evidence. Eur J Clin Invest 39[Suppl 2]: 50-67, 2009
53. Sorokin A, Kohan DE: Physiology and pathology of endothelin-1 in renal mesangium. Am J Physiol Renal Physiol 285: F579-F589, 2003
54. Rabelink TJ, Kohan DE: Endothelin receptor blockade in patients with diabetic nephropathy. Contrib Nephrol 172: 235-242, 2011
55. Rafnsson A, Böhm F, Settergren M, Gonon A, Brismar K, Pernow J: The endothelin receptor antagonist bosentan improves peripheral endothelial function in patients with type 2 diabetes mellitus and microalbuminuria: A randomised trial. Diabetologia 55: 600-607, 2012
56. Wiggins JE, Patel SR, Shedden KA, Goyal M, Wharram BL, Martini S, Kretzler M, Wiggins RC: NFkappaB promotes inflammation, coagulation, andfibrosis in the agingglomerulus. JAm Soc Nephrol 21: 587-597, 2010
57. Tilstra JS, Robinson AR, Wang J, Gregg SQ, Clauson CL, Reay DP, Nasto LA, St Croix CM, Usas A, Vo N, Huard J, Clemens PR, Stolz DB, Guttridge DC, Watkins SC, Garinis GA, Wang Y, Niedernhofer LJ, Robbins PD: NF-kB inhibition delays DNA damage-induced senescence and aging in mice. J Clin Invest 122: 2601-2612, 2012
58. Wharram BL, Goyal M, Wiggins JE, Sanden SK, Hussain S, Filipiak WE, Saunders TL, Dysko RC, Kohno K, Holzman LB, Wiggins RC: Podocyte depletion causes glomerulosclerosis: Diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol 16: 2941-2952, 2005
59. Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, RennkeHG, CoplonNS, Sun L,MeyerTW: Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 99: 342-348, 1997
60. Meyer TW, Bennett PH, Nelson RG: Podocyte number predicts longterm urinary albumin excretion in Pima Indians with type II diabetes and microalbuminuria. Diabetologia 42: 1341-1344, 1999
61. Budde K, Neumayer HH, Salant DJ, Cybulsky AV, Coleman DL, Sterzel RB: Glomerular epithelial cell products stimulate mesangial cell proliferation in culture. Kidney Int 52: 733-741, 1997
62. LeeHS: Paracrine role for TGF-b-inducedCTGF and VEGF inmesangial matrix expansion in progressive glomerular disease. Histol Histopathol 27: 1131-1141, 2012
63. Ge Y, Stricklett PK, Hughes AK, Yanagisawa M, Kohan DE: Collecting duct-specific knockout of the endothelin A receptor alters renal vasopressin responsiveness, but not sodium excretion or blood pressure. Am J Physiol Renal Physiol 289: F692-F698, 2005
64. Bagnall AJ, Kelland NF, Gulliver-Sloan F, Davenport AP, Gray GA, Yanagisawa M, Webb DJ, Kotelevtsev YV: Deletion of endothelial cell endothelin B receptors does not affect blood pressure or sensitivity to salt. Hypertension 48: 286-293, 2006
65. Schiwek D, EndlichN, Holzman L, Holthöfer H, KrizW, Endlich K: Stable expression of nephrin and localization to cell-cell contacts in novel murine podocyte cell lines. Kidney Int 66: 91-101, 2004
66. Bollée G, Flamant M, Schordan S, Fligny C, Rumpel E, Milon M, Schordan E, Sabaa N, Vandermeersch S, Galaup A, Rodenas A, Casal I, Sunnarborg SW, Salant DJ, Kopp JB, Threadgill DW, Quaggin SE, Dussaule JC, Germain S, Mesnard L, Endlich K, Boucheix C, Belenfant X, Callard P, Endlich N, Tharaux PL: Epidermal growth factor receptor promotes glomerular injury and renal failure in rapidly progressive crescentic glomerulonephritis. Nat Med 17: 1242-1250, 2011
67. Gysembergh A, Lemaire S, Piot C, Sportouch C, Richard S, Kloner RA, Przyklenk K: Pharmacological manipulation of Ins(1,4,5)P3 signalingmimics preconditioning in rabbit heart. Am J Physiol 277: H2458-H2469, 1999